Vaccination against Her-2/neu, with focus on peptide-based vaccines

Roskoski, 2004, The ErbB/HER receptor protein-tyrosine kinases and cancer, Biochem Biophys Res Commun, 319, 1, 10.1016/j.bbrc.2004.04.150 Slamon, 1987, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106 King, 1985, Amplification of a novel v-erbB-related gene in a human mammary carcinoma, Science, 229, 974, 10.1126/science.2992089 Ross, 2009, The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine, Oncologist, 14, 320, 10.1634/theoncologist.2008-0230 Iqbal, 2014, Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications, Mol Biol Int, 2014, 852748, 10.1155/2014/852748 Oh, 2020, HER2-targeted therapies – a role beyond breast cancer, Nat Rev Clin Oncol, 17, 33, 10.1038/s41571-019-0268-3 Fisk, 1995, Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines, J Exp Med, 181, 2109, 10.1084/jem.181.6.2109 Arienti, 2019, Epidermal growth factor receptor family and its role in gastric cancer, Front Oncol, 9, 1308, 10.3389/fonc.2019.01308 Hynes, 1994, The biology of erbB-2/neu/HER-2 and its role in cancer, Biochim Biophys Acta, 1198, 165 Slamon, 1989, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, 244, 707, 10.1126/science.2470152 Yu, 2000, Overexpression of ErbB2 in cancer and ErbB2-targeting strategies, Oncogene, 19, 6115, 10.1038/sj.onc.1203972 Cui, 2018, HER2-based immunotherapy for breast cancer, Cancer Biother Radiopharm, 33, 169, 10.1089/cbr.2017.2327 Tai, 2010, The role of HER2 in cancer therapy and targeted drug delivery, J Control Release, 146, 264, 10.1016/j.jconrel.2010.04.009 Witsch, 2011, Generation and characterization of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies, Int Immunol, 23, 391, 10.1093/intimm/dxr028 Schneble, 2015, Breast cancer immunotherapy, Maedica (Buchar), 10, 185 Lesterhuis, 2011, Cancer immunotherapy – revisited, Nat Rev Drug Discov, 10, 591, 10.1038/nrd3500 Costa, 2020, Clinical development of immunotherapies for HER2(+) breast cancer: a review of HER2-directed monoclonal antibodies and beyond, NPJ Breast Cancer, 6, 10, 10.1038/s41523-020-0153-3 Strebhardt, 2008, Paul Ehrlich's magic bullet concept: 100 years of progress, Nat Rev Cancer, 8, 473, 10.1038/nrc2394 Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, 12, 252, 10.1038/nrc3239 Wiedermann, 2013, Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines, Breast Cancer Res Treat, 138, 1, 10.1007/s10549-013-2410-8 Citri, 2006, EGF-ERBB signalling: towards the systems level, Nat Rev Mol Cell Biol, 7, 505, 10.1038/nrm1962 Moasser, 2007, The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis, Oncogene, 26, 6469, 10.1038/sj.onc.1210477 Yarden, 2001, Untangling the ErbB signalling network, Nat Rev Mol Cell Biol, 2, 127, 10.1038/35052073 Hsu, 2016, The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer, Cancer Metastasis Rev, 35, 575, 10.1007/s10555-016-9649-6 Exman, 2021, HER2-positive metastatic breast cancer: a comprehensive review, Clin Adv Hematol Oncol, 19, 40 Pallerla, 2021, Cancer vaccines, treatment of the future: with emphasis on HER2-positive breast cancer, Int J Mol Sci, 22, 779, 10.3390/ijms22020779 Wang, 2019, Targeted therapeutic options and future perspectives for HER2-positive breast cancer, Signal Transduct Target Ther, 4, 34, 10.1038/s41392-019-0069-2 Klapper, 1997, A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors, Oncogene, 14, 2099, 10.1038/sj.onc.1201029 Klapper, 2000, Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2, Cancer Res, 60, 3384 Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, 344, 783, 10.1056/NEJM200103153441101 Piccart-Gebhart, 2005, Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer, N Engl J Med, 353, 1659, 10.1056/NEJMoa052306 Smith, 2012, Pertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancer, Drugs Today (Barc), 48, 713, 10.1358/dot.2012.48.11.1885879 Sakai, 2007, Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway, Cancer Sci, 98, 1498, 10.1111/j.1349-7006.2007.00553.x Nahta, 2004, The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells, Cancer Res, 64, 2343, 10.1158/0008-5472.CAN-03-3856 Scheuer, 2009, Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models, Cancer Res, 69, 9330, 10.1158/0008-5472.CAN-08-4597 Baselga, 2012, Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer, N Engl J Med, 366, 109, 10.1056/NEJMoa1113216 Scolnik, 2009, mAbs: a business perspective, MAbs, 1, 179, 10.4161/mabs.1.2.7736 Chames, 2009, Therapeutic antibodies: successes, limitations and hopes for the future, Br J Pharmacol, 157, 220, 10.1111/j.1476-5381.2009.00190.x Martins, 2019, Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance, Nat Rev Clin Oncol, 16, 563, 10.1038/s41571-019-0218-0 Fares, 2019, Mechanisms of Resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients?, Am Soc Clin Oncol Educ Book, 39, 147, 10.1200/EDBK_240837 Verma, 2018, A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors, J Immunother Cancer, 6, 128, 10.1186/s40425-018-0442-7 van Holstein, 2019, Efficacy and adverse events of immunotherapy with checkpoint inhibitors in older patients with cancer, Drugs Aging, 36, 927, 10.1007/s40266-019-00697-2 Ishii, 2019, Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy, Core Evid, 14, 51, 10.2147/CE.S217848 Bettaieb, 2017, Precision medicine in breast cancer: reality or utopia?, J Transl Med, 15, 139, 10.1186/s12967-017-1239-z Torka, 2019, Mechanisms of resistance to monoclonal antibodies (mAbs) in lymphoid malignancies, Curr Hematol Malig Rep, 14, 426, 10.1007/s11899-019-00542-8 Isabwe, 2018, Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes, J Allergy Clin Immunol, 142, 159, 10.1016/j.jaci.2018.02.018 Pintea, 2021, Hypersensitivity reactions to monoclonal antibodies: classification and treatment approach (Review), Exp Ther Med, 22, 949, 10.3892/etm.2021.10381 Hendrikx, 2017, Fixed dosing of monoclonal antibodies in oncology, Oncologist, 22, 1212, 10.1634/theoncologist.2017-0167 Price, 2018, Trastuzumab infusion reactions in breast cancer. Should we routinely observe after the first dose?, Eur J Hosp Pharm, 25, 331, 10.1136/ejhpharm-2016-001155 Chen, 2016, Cardiotoxicity associated with targeted cancer therapies, Mol Clin Oncol, 4, 675, 10.3892/mco.2016.800 Lollini, 2006, Vaccines for tumour prevention, Nat Rev Cancer, 6, 204, 10.1038/nrc1815 Datta, 2014, Optimizing dendritic cell-based approaches for cancer immunotherapy, Yale J Biol Med, 87, 491 Mehta-Damani, 1994, Generation of antigen-specific CD8+ CTLs from naive precursors, J Immunol, 153, 996, 10.4049/jimmunol.153.3.996 Mehta-Damani, 1995, Generation of antigen-specific CD4+ T cell lines from naive precursors, Eur J Immunol, 25, 1206, 10.1002/eji.1830250511 Norell, 2010, Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial, J Transl Med, 8, 53, 10.1186/1479-5876-8-53 Quaglino, 2011, Chimeric DNA vaccines against ErbB2+ carcinomas: from mice to humans, Cancers (Basel), 3, 3225, 10.3390/cancers3033225 Riccardo, 2017, Chimeric DNA vaccines: an effective way to overcome immune tolerance, Curr Top Microbiol Immunol, 405, 99 Sharpe, 2009, Mechanisms of costimulation, Immunol Rev, 229, 5, 10.1111/j.1600-065X.2009.00784.x Mittendorf, 2008, The E75 HER2/neu peptide vaccine, Cancer Immunol Immunother, 57, 1511, 10.1007/s00262-008-0540-3 Patil, 2010, Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial, J Am Coll Surg, 210, 140, 10.1016/j.jamcollsurg.2009.10.022 Ayoub, 2019, Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches, Breast Cancer (Dove Med Press), 11, 53 Clive, 2012, The GP2 peptide: a HER2/neu-based breast cancer vaccine, J Surg Oncol, 105, 452, 10.1002/jso.21723 Sears, 2011, AE37: a novel T-cell-eliciting vaccine for breast cancer, Expert Opin Biol Ther, 11, 1543, 10.1517/14712598.2011.616889 Gillogly, 2004, Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer, Cancer Immunol Immunother, 53, 490, 10.1007/s00262-003-0463-y Xu, 2012, CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines, Vaccine, 30, 2805, 10.1016/j.vaccine.2012.02.031 Ladjemi, 2010, Anti-HER2 vaccines: new prospects for breast cancer therapy, Cancer Immunol Immunother, 59, 1295, 10.1007/s00262-010-0869-2 Lu, 2020, Development of therapeutic antibodies for the treatment of diseases, J Biomed Sci, 27, 1, 10.1186/s12929-019-0592-z Jasinska, 2003, Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu, Int J Cancer, 107, 976, 10.1002/ijc.11485 Schwarzkopf, 1996, Effectivity of alternative adjuvants in comparison to Freund's complete adjuvant, ALTEX, 13, 22 Wagner, 2007, Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice, Breast Cancer Res Treat, 106, 29, 10.1007/s10549-006-9469-4 Moser, 2013, Influenza virosomes as vaccine adjuvant and carrier system, Expert Rev Vaccines, 12, 779, 10.1586/14760584.2013.811195 Wiedermann, 2010, A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study, Breast Cancer Res Treat, 119, 673, 10.1007/s10549-009-0666-9 Tobias, 2017, Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide, BMC Cancer, 17, 118, 10.1186/s12885-017-3098-7 Malito, 2012, Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197, Proc Natl Acad Sci U S A, 109, 5229, 10.1073/pnas.1201964109 Kamboj, 2001, Immunization with Haemophilus influenzae type b-CRM(197) conjugate vaccine elicits a mixed Th1 and Th2 CD(4+) T cell cytokine response that correlates with the isotype of antipolysaccharide antibody, J Infect Dis, 184, 931, 10.1086/323342 Tobias, 2020, A New strategy toward B cell-based cancer vaccines by active immunization with mimotopes of immune checkpoint inhibitors, Front Immunol, 11, 895, 10.3389/fimmu.2020.00895 Wiedermann, 2021, Clinical and immunologic responses to a B-cell epitope vaccine in patients with HER2/neu-overexpressing advanced gastric cancer-results from phase Ib trial IMU.ACS.001, Clin Cancer Res, 27, 3649, 10.1158/1078-0432.CCR-20-3742 Maglakelidze, 2021, A phase 1b/2 open-label study with randomization in phase 2 of Imu-131 Her2/Neu peptide vaccine plus standard of care chemotherapy in patients with Her2/Neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction, Cancer Res, 81, 10.1158/1538-7445.AM2021-CT107 Lewis, 1993, Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies, Cancer Immunol Immunother, 37, 255, 10.1007/BF01518520 Sato, 2013, Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells, Cancer Sci, 104, 1618, 10.1111/cas.12290 Majumder, 2021, The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers, Sci Rep, 11, 9091, 10.1038/s41598-021-88683-w Allen, 2007, Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo, J Immunol, 179, 472, 10.4049/jimmunol.179.1.472 Garrett, 2007, Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu, J Immunol, 178, 7120, 10.4049/jimmunol.178.11.7120 Kaumaya, 2020, B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine, Future Oncol, 16, 1767 Wallis, 2020, A liposome-based cancer vaccine for a rapid and high-titre anti-ErbB-2 antibody response, Eur J Pharm Sci, 152, 105456, 10.1016/j.ejps.2020.105456 Okarvi, 2019, Development of the tumor-specific antigen-derived synthetic peptides as potential candidates for targeting breast and other possible human carcinomas, Molecules, 24, 3142, 10.3390/molecules24173142 Brossart, 2000, Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells, Blood, 96, 3102, 10.1182/blood.V96.9.3102 Mittendorf, 2014, Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients, Ann Oncol, 25, 1735, 10.1093/annonc/mdu211 Clifton, 2020, Results of a randomized phase IIb trial of nelipepimut-S + trastuzumab versus trastuzumab to prevent recurrences in patients with high-risk HER2 low-expressing breast cancer, Clin Cancer Res, 26, 2515, 10.1158/1078-0432.CCR-19-2741 Mittendorf, 2019, Efficacy and safety analysis of nelipepimut-S vaccine to prevent breast cancer recurrence: a randomized, multicenter, phase III clinical trial, Clin Cancer Res, 25, 4248, 10.1158/1078-0432.CCR-18-2867 Dillon, 2020, Evaluating nelipepimut-S in the treatment of breast cancer: a short report on the emerging data, Breast Cancer (Dove Med Press), 12, 69 Carmichael, 2010, Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04, Cancer, 116, 292, 10.1002/cncr.24756 Mittendorf, 2016, Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence, Oncotarget, 7, 66192, 10.18632/oncotarget.11751 Clifton, 2017, Results of a phase Ib trial of combination immunotherapy with a CD8+ T cell eliciting vaccine and trastuzumab in breast cancer patients, Ann Surg Oncol, 24, 2161, 10.1245/s10434-017-5844-0 Holmes, 2008, Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine, J Clin Oncol, 26, 3426, 10.1200/JCO.2007.15.7842 Mittendorf, 2016, Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence, Ann Oncol, 27, 1241, 10.1093/annonc/mdw150 Knutson, 2001, Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients, J Clin Invest, 107, 477, 10.1172/JCI11752 Disis, 2009, Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer, J Clin Oncol, 27, 4685, 10.1200/JCO.2008.20.6789 Park, 2020, Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome, Nat Commun, 11, 6175, 10.1038/s41467-020-19933-0 Waidhauser, 2020, Chemotherapy markedly reduces B cells but not T cells and NK cells in patients with cancer, Cancer Immunol Immunother, 69, 147, 10.1007/s00262-019-02449-y Mohan, 2018, Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers, Antib Ther, 1, 13 Bekaii-Saab, 2019, Phase I immunotherapy trial with two chimeric HER-2 B-cell peptide vaccines emulsified in montanide ISA 720VG and nor-MDP adjuvant in patients with advanced solid tumors, Clin Cancer Res, 25, 3495, 10.1158/1078-0432.CCR-18-3997 Gordon, 2020, The role of the tumor microenvironment in developing successful therapeutic and secondary prophylactic breast cancer vaccines, Vaccines (Basel), 8, 529, 10.3390/vaccines8030529 Li, 2021, Recent progress on immunotherapy for breast cancer: tumor microenvironment, nanotechnology and more, Front Bioeng Biotechnol, 9, 680315, 10.3389/fbioe.2021.680315 Crosby, 2021, Cancer vaccines: the importance of targeting oncogenic drivers and the utility of combinations with immune checkpoint inhibitors, Oncotarget, 12, 1, 10.18632/oncotarget.27861 Mougel, 2019, Therapeutic cancer vaccine and combinations with antiangiogenic therapies and immune checkpoint blockade, Front Immunol, 10, 467, 10.3389/fimmu.2019.00467 Tobias, 2021, Emerging targets for anti-cancer vaccination: PD-1, ESMO Open, 6, 100278, 10.1016/j.esmoop.2021.100278 Guo, 2021, First prototype checkpoint inhibitor B-cell epitope vaccine (PD1-Vaxx) en route to human Phase 1 clinical trial in Australia and USA: exploiting future novel synergistic vaccine combinations, Br J Cancer, 6, 100278